MB-101 is under clinical development by Mustang Bio and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect MB-101’s likelihood of approval (LoA) and phase transition for Ependymoma took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MB-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

MB-101 overview

MB-101 is under development for the treatment of recurrent or refractory glioblastoma multiforme. It is administered through intratumoral infusion or intracavitary or intraventricular catheter, intracerebroventricular (ICV) delivery. The therapy comprises of central memory enriched T cells lentivirally transduced to express an IL13R-apha2-specific, hinge-optimized, 41BB-costimulatory chimeric receptor and a truncated CD19. It acts by targeting interleukin 13 receptor alpha-2 (IL13R alpha 2).

Mustang Bio overview

Mustang Bio is an US based developer of cell and gene therapies for the treatment of AML and brain cancer.

Quick View MB-101 LOA Data

Report Segments
  • Innovator
Drug Name
  • MB-101
Administration Pathway
  • Intracavitary
  • Intracerebral
  • Intratumor
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.